In this combinatorial therapy, lixisenatide exhibited substantial decreases in HbA1C (0.70.8%) and body weight (1.8 kg)
But "stronger" is misleading because they work through different mechanisms
CXCR1/2, CXCR3, CXCR4, CXCR7, CXC motif receptor-1/2, -3, -4, -7
Studies by Coolican et al
Novo moved fast, launched in January 2026, and now holds a meaningful head start over Lilly's orforglipron, still awaiting FDA review
Research Applications Muscle growth and hypertrophy research Muscle recovery and regeneration studies Protein synthesis research Satellite cell activation studies Muscle wasting disorder research Exercise physiology studies Body composition optimization research Sarcopenia and age-related muscle loss studies Metabolic disorder and insulin sensitivity research Wound healing and tissue repair studies Neuroprotection and neurogenesis research Bone formation and osteoporosis studies Safety Profile IGF-1 LR3 safety data in humans is severely limited due to the absence of controlled clinical trials and systematic safety assessments
